Ensysce stockholders approve reverse stock split authorization and director elections at annual meeting

Ensysce Biosciences, Inc.

Approved issuance of shares/warrants to investors: 3,102,053 for, 210,141 against (3,995,063 broker non-votes).
Authorized reverse stock split with ratio range 1-for-10 to 1-for-40; board sets exact ratio: 4,561,369 for, 1,989,571 against.
Elected Class III directors Dr. Lynn Kirkpatrick, Dr. Adam Levin, and Mr. Steve Martin (each >2M votes for).
Ratified Moss Adams LLP as auditor for FY 2024: 5,978,860 for, 259,207 against, 1,250,026 abstentions.
Fifth proposal to adjourn meeting if needed was not voted on.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.